The Sirens of Precision Medicine in MASLD: Are We Sailing Beyond the Evidence?

Key Takeaways for GI Nurses

• Precision medicine approaches in MASLD (metabolic dysfunction-associated steatotic liver disease) — including genetic risk scoring, biomarker panels, and individualized pharmacotherapy — are advancing rapidly, but this commentary raises important questions about whether clinical enthusiasm is outpacing robust evidence.
• Nurses should be cautious about overpromising personalized risk stratification or treatment outcomes to patients until validated, reproducible data support these tools in diverse populations.
• Staying informed about the evolving evidence base for MASLD diagnostics and therapeutics allows nurses to provide balanced, realistic patient education rather than relying on emerging but unproven technologies.
• This underscores the ongoing need for critical appraisal skills within GI nursing practice, particularly as "precision" or "personalized" medicine terminology becomes more prevalent in hepatology.

Clinical Relevance

MASLD (formerly NAFLD) has become one of the most common reasons for GI and hepatology referrals, and endoscopy and GI nurses are increasingly involved in patient education, pre-procedure counseling, and long-term disease management support for this population. As precision medicine tools — such as polygenic risk scores, non-invasive biomarker panels, and genotype-guided pharmacologic interventions — gain visibility in the literature and at conferences, nurses are often the first point of contact when patients ask about "personalized" testing or treatment options they've read about online. This commentary's cautionary framing is a timely reminder that not all emerging technologies have cleared the evidentiary bar needed for routine clinical adoption.

For nursing practice, this means maintaining a healthy skepticism when new MASLD risk-stratification tools or targeted therapies are introduced into clinical pathways. Nurses coordinating fibrosis staging (via FibroScan, ELF testing, or MRE), liver biopsy scheduling, or metabolic risk counseling should understand that many precision-medicine claims are still investigational, based on limited or homogeneous study populations, or lack long-term outcome data. This is particularly relevant when counseling patients from diverse ethnic or socioeconomic backgrounds, as many MASLD biomarker studies have historically underrepresented these groups — a limitation directly relevant to equitable care delivery.

From a unit operations standpoint, this article supports the case for continued investment in nursing education around evidence-based hepatology updates, journal clubs, and multidisciplinary case conferences with hepatology providers. GI nurses are well positioned to serve as a check-and-balance in clinical workflows — flagging when a "precision" intervention or test is being adopted ahead of guideline endorsement, and ensuring patient consent conversations accurately reflect the current strength (or limitations) of supporting evidence. This also reinforces the value of nurses participating in research literacy training, enabling more confident engagement with rapidly evolving hepatology literature.

Bottom Line

As MASLD care increasingly incorporates precision-medicine language and tools, GI nurses should approach these innovations with informed caution — supporting patients with accurate, evidence-grounded education while recognizing that many personalized diagnostic and therapeutic strategies in MASLD remain unproven at scale and are not yet ready to replace established, guideline-based standards of care.